H.C. Wainwright keeps USD 65.00 target for Legend Biotech stock

Published on 10/17/2026 at 18:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Thirteen analysts set a USD 45.62 average target on October 14, 2026. Legend Biotech stock costs USD 18.48 on October 16, down 6.67 percent on Nasdaq.

Analyst targets and valuation

H.C. Wainwright maintained a USD 65.00 target and Buy rating on October 15, 2026.
Thirteen analysts set a USD 45.62 average target on October 14, 2026.
Legend Biotech stock was last at USD 18.48 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 6.67 percent versus the prior close of USD 19.80.
Legend Biotech had a USD 3.4 billion market capitalization on October 16, 2026.

LEGN, US52490G1022, Illustration mit AI erstellt.

H.C. Wainwright maintained a Buy rating and a USD 65.00 price target for Legend Biotech on October 15, 2026, according to Investing.com. The target stood 251.73 percent above the Nasdaq price of USD 18.48. Legend Biotech stock was last at USD 18.48 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 6.67 percent from the prior close of USD 19.80.

Analyst targets stay elevated

Investing.com listed 13 analysts with an average 12-month target of USD 45.62 on October 14, 2026. That average was 146.86 percent above the USD 18.48 price, while the high target reached USD 68.00 and the low target stood at USD 24.00.

Stock remains near its yearly low

Legend Biotech traded within a USD 16.24 to USD 37.50 52-week range on October 16, 2026. The last price was 13.79 percent above the low and 50.72 percent below the high. Trading volume reached 2,961,655 shares, compared with an average volume of 2,344,206 shares, a 26.32 percent difference.

Valuation and market scale

Legend Biotech had a market capitalization of USD 3.4 billion on October 16, 2026. Its price-to-earnings ratio was negative 36.24 on the same date. The company operates in biotechnology and develops cell therapies, including CAR-T treatments for cancer.

Comparison with peers

Legend Biotech (Nasdaq, USD): minus 6.67 percent, P/E -36.24, market capitalization USD 3.4 billion

Bristol-Myers Squibb (NYSE, USD): minus 1.35 percent, P/E 13.16, market capitalization USD 122.1 billion

Gilead Sciences (Nasdaq, USD): minus 0.75 percent, P/E -58.50, market capitalization USD 193.7 billion

Price and investor perspective

The contrast is clear in the valuation figures: Legend Biotech is much smaller than both comparison companies, while its share price sits materially closer to its 52-week low than its high. The current analyst targets therefore remain the main dated market reference for the stock.

Market context: Market report S&P 500.

More news and analyses on Legend Biotech stock